A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.
Advanced Solid Tumors
DRUG: SHR-3821 injection
DLT, 3 weeks|AE, Screening up to study completion, an average of 1 year|MTD, 3 weeks|RP2D, Screening up to study completion, an average of 1 year
Blood concentration of SHR-3821 after single and continuous administration, Screening up to study completion, an average of 1 year|PK parameters of SHR-3821 after single and continuous administration: Tmax, Screening up to study completion, an average of 1 year|PK parameters of SHR-3821 after single and continuous administration: Cmax, Screening up to study completion, an average of 1 year|PK parameters of SHR-3821 after single and continuous administration: AUC0-t, Screening up to study completion, an average of 1 year|Drug Resistant Antibody (ADA) to SHR-3821, Screening up to study completion, an average of 1 year|Objective response rate (ORR), Screening up to study completion, an average of 1 year|Disease control rate (DCR), Screening up to study completion, an average of 1 year|Progression-free survival (PFS), Screening up to study completion, an average of 1 year|Overall survival (OS), Screening up to study completion, an average of 1 year
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.